Container closure integrity, which is verified by container closure integrity testing (CCIT), is critical to ensure the sterility of drug products. Physical, chemical, and biological assessments must be carried out to make sure components are compatible and fit for use. USP <661.1> <661.2> & <382> will be official by the end 2025. This webinar will review the changes that these new general chapters will bring to CCIT.
You can expect to learn the following form this webinar:
• Container closure requirements for parenteral products
• The changes resulting from USP <382> <661.1> and <661.2>
• The capabilities of Nelson Labs to meet the new chapter requirements